268 related articles for article (PubMed ID: 16115884)
1. Disease-related modifications in tau affect the interaction between Fyn and Tau.
Bhaskar K; Yen SH; Lee G
J Biol Chem; 2005 Oct; 280(42):35119-25. PubMed ID: 16115884
[TBL] [Abstract][Full Text] [Related]
2. AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.
Cochran JN; Diggs PV; Nebane NM; Rasmussen L; White EL; Bostwick R; Maddry JA; Suto MJ; Roberson ED
J Biomol Screen; 2014 Dec; 19(10):1338-49. PubMed ID: 25156556
[TBL] [Abstract][Full Text] [Related]
3. Fyn depletion ameliorates tau
Liu G; Fiock KL; Levites Y; Golde TE; Hefti MM; Lee G
Acta Neuropathol Commun; 2020 Jul; 8(1):108. PubMed ID: 32665013
[TBL] [Abstract][Full Text] [Related]
4. Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease.
Lau DH; Hogseth M; Phillips EC; O'Neill MJ; Pooler AM; Noble W; Hanger DP
Acta Neuropathol Commun; 2016 May; 4(1):49. PubMed ID: 27193083
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.
Usardi A; Pooler AM; Seereeram A; Reynolds CH; Derkinderen P; Anderton B; Hanger DP; Noble W; Williamson R
FEBS J; 2011 Aug; 278(16):2927-37. PubMed ID: 21692989
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.
Derkinderen P; Scales TM; Hanger DP; Leung KY; Byers HL; Ward MA; Lenz C; Price C; Bird IN; Perera T; Kellie S; Williamson R; Noble W; Van Etten RA; Leroy K; Brion JP; Reynolds CH; Anderton BH
J Neurosci; 2005 Jul; 25(28):6584-93. PubMed ID: 16014719
[TBL] [Abstract][Full Text] [Related]
7. Tau interacts with src-family non-receptor tyrosine kinases.
Lee G; Newman ST; Gard DL; Band H; Panchamoorthy G
J Cell Sci; 1998 Nov; 111 ( Pt 21)():3167-77. PubMed ID: 9763511
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of tau by fyn: implications for Alzheimer's disease.
Lee G; Thangavel R; Sharma VM; Litersky JM; Bhaskar K; Fang SM; Do LH; Andreadis A; Van Hoesen G; Ksiezak-Reding H
J Neurosci; 2004 Mar; 24(9):2304-12. PubMed ID: 14999081
[TBL] [Abstract][Full Text] [Related]
9. Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines.
Xia D; Li C; Götz J
Biochim Biophys Acta; 2015 May; 1852(5):913-24. PubMed ID: 25558816
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy.
Bhaskar K; Hobbs GA; Yen SH; Lee G
Neuropathol Appl Neurobiol; 2010 Oct; 36(6):462-77. PubMed ID: 20609109
[TBL] [Abstract][Full Text] [Related]
11. The microtubule-associated protein tau is also phosphorylated on tyrosine.
Lebouvier T; Scales TM; Williamson R; Noble W; Duyckaerts C; Hanger DP; Reynolds CH; Anderton BH; Derkinderen P
J Alzheimers Dis; 2009; 18(1):1-9. PubMed ID: 19542604
[TBL] [Abstract][Full Text] [Related]
12. Tau and src family tyrosine kinases.
Lee G
Biochim Biophys Acta; 2005 Jan; 1739(2-3):323-30. PubMed ID: 15615649
[TBL] [Abstract][Full Text] [Related]
13. Binding of Fyn to MAP-2c through an SH3 binding domain. Regulation of the interaction by ERK2.
Zamora-Leon SP; Lee G; Davies P; Shafit-Zagardo B
J Biol Chem; 2001 Oct; 276(43):39950-8. PubMed ID: 11546790
[TBL] [Abstract][Full Text] [Related]
14. A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity.
Rush T; Roth JR; Thompson SJ; Aldaher AR; Cochran JN; Roberson ED
Neurobiol Dis; 2020 Feb; 134():104668. PubMed ID: 31698056
[TBL] [Abstract][Full Text] [Related]
15. Tau-S214 Phosphorylation Inhibits Fyn Kinase Interaction and Increases the Decay Time of NMDAR-mediated Current.
Jos S; Poulose R; Kambaru A; Gogoi H; Dalavaikodihalli Nanjaiah N; Padmanabhan B; Mehta B; Padavattan S
J Mol Biol; 2024 Feb; 436(4):168445. PubMed ID: 38218365
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of Src homology 3 domain association with the proline-rich domain of dynamins: specificity, occlusion, and the effects of phosphorylation.
Solomaha E; Szeto FL; Yousef MA; Palfrey HC
J Biol Chem; 2005 Jun; 280(24):23147-56. PubMed ID: 15834155
[TBL] [Abstract][Full Text] [Related]
17. Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Li C; Götz J
J Alzheimers Dis; 2018; 64(1):205-221. PubMed ID: 29782321
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus NS5A protein binds the SH3 domain of the Fyn tyrosine kinase with high affinity: mutagenic analysis of residues within the SH3 domain that contribute to the interaction.
Shelton H; Harris M
Virol J; 2008 Feb; 5():24. PubMed ID: 18267011
[TBL] [Abstract][Full Text] [Related]
19. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.
Larson M; Sherman MA; Amar F; Nuvolone M; Schneider JA; Bennett DA; Aguzzi A; Lesné SE
J Neurosci; 2012 Nov; 32(47):16857-71a. PubMed ID: 23175838
[TBL] [Abstract][Full Text] [Related]
20. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease.
Liu W; Zhao J; Lu G
Biochem Biophys Res Commun; 2016 Sep; 478(2):852-7. PubMed ID: 27520374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
